Mangalam Drugs and Organics Falls to 52-Week Low of Rs.23.45

Stock Price Movement and Market Context

On 22 December 2025, Mangalam Drugs and Organics recorded its lowest price in the past year at Rs.23.45. This new low comes after a sequence of five consecutive days of price declines, although the stock showed a modest gain on the day it hit this level, outperforming its sector by 1.31%. Despite this slight uptick, the stock remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent downward trend.

In contrast, the broader market has demonstrated resilience. The Sensex opened 216.54 points higher and further climbed by 238.22 points to close at 85,384.12, representing a 0.54% gain. The Sensex is trading near its 52-week high of 86,159.02, just 0.91% away, supported by bullish moving averages where the 50-day moving average remains above the 200-day moving average. Mid-cap stocks have also led the market rally, with the BSE Mid Cap index gaining 0.66% on the same day.

Financial Performance and Profitability Trends

The stock’s decline is reflective of the company’s financial performance over recent periods. Mangalam Drugs and Organics has reported negative results for three consecutive quarters, with net sales for the latest six months at Rs.106.89 crores showing a contraction of 31.69% compared to previous periods. The company’s profit after tax (PAT) for the same period stands at a loss of Rs.21.15 crores, also reflecting a decline of 31.69%.

Interest expenses have risen by 20.61% to Rs.9.07 crores in the latest six months, adding to the financial strain. The company’s return on equity (ROE) averages 5.83%, indicating limited profitability relative to shareholders’ funds. Furthermore, the debt to EBITDA ratio is at 5.66 times, signalling a high level of leverage and a constrained ability to service debt obligations.

Long-Term Performance and Shareholding Concerns

Over the past year, Mangalam Drugs and Organics has recorded a total return of -79.08%, significantly underperforming the Sensex, which has shown a positive return of 9.40% during the same period. The stock’s performance has also lagged behind the BSE500 index in each of the last three annual periods, highlighting a consistent trend of underperformance relative to broader market benchmarks.

Adding to the stock’s pressure is the high proportion of promoter shares pledged, which currently stands at 34.58%. This represents an increase of 21.35% over the last quarter. Elevated pledged shareholding can exert additional downward pressure on the stock price, particularly in falling markets, as it may lead to forced selling or margin calls.

Valuation and Risk Factors

The stock is considered risky when compared to its historical average valuations. Over the last year, profits have declined by 306.3%, a steep contraction that has contributed to the stock’s sharp price fall. The company’s operating losses and weak long-term fundamental strength have been key factors in the stock’s valuation challenges.

Despite the broader market’s positive momentum, Mangalam Drugs and Organics remains in a subdued position, trading well below its 52-week high of Rs.129.90. The stock’s current price level reflects the market’s assessment of the company’s financial health and operational performance over recent quarters.

Summary of Key Financial Indicators

Mangalam Drugs and Organics’ recent financial data highlights several areas of concern. Net sales for the latest six months stand at Rs.106.89 crores, reflecting a contraction of nearly one-third compared to prior periods. The company’s net loss of Rs.21.15 crores over the same timeframe points to ongoing challenges in generating profitability. Interest costs have risen to Rs.9.07 crores, increasing the financial burden.

The company’s leverage remains elevated, with a debt to EBITDA ratio of 5.66 times, while the average return on equity of 5.83% indicates limited returns on shareholder capital. The stock’s price performance over the last year, down by more than 79%, further illustrates the market’s cautious stance.

Promoter share pledging has increased significantly, now accounting for over one-third of promoter holdings, which may contribute to additional volatility in the stock price during market downturns.

Market Position and Sector Comparison

Within the Pharmaceuticals & Biotechnology sector, Mangalam Drugs and Organics’ stock has not mirrored the broader market’s positive trajectory. While the Sensex and mid-cap indices have shown gains, the company’s share price remains under pressure, trading below all major moving averages and at a level not seen in the past year.

This divergence highlights the specific challenges faced by the company relative to its sector peers and the broader market environment.

Conclusion

The fall of Mangalam Drugs and Organics to its 52-week low of Rs.23.45 reflects a combination of subdued financial results, elevated debt levels, and increased promoter share pledging. Despite a slight recovery after a series of declines, the stock remains below key technical indicators and has underperformed market benchmarks significantly over the past year. These factors collectively illustrate the hurdles the company is currently navigating within the Pharmaceuticals & Biotechnology sector.

Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Start Saving Now →